Highlights of 2024: γδ T cells and bad blood.

IF 3.2 4区医学 Q3 CELL BIOLOGY

Immunology & Cell Biology Pub Date : 2025-03-09 DOI:10.1111/imcb.70012

Matthias Eberl

引用次数: 0

Abstract

In this manuscript for the "Highlights of 2024" series, this is me trying to summarize recent discoveries regarding the emerging regulatory and effector roles of γδ T cells during sepsis, both in human patients and in mouse models. The new findings not only aid our understanding of key immunological and pathophysiological pathways that hit differently during the course of the disease but may also have clinical relevance for a life-threatening condition that requires swift intervention and tailored patient management.

查看原文本刊更多论文

2024年的亮点：γδ T细胞和坏血。

在这篇“2024年亮点”系列的手稿中，我试图总结关于γδ T细胞在人类患者和小鼠模型中败血症期间新兴的调节和效应作用的最新发现。这些新发现不仅有助于我们理解在疾病过程中不同的关键免疫和病理生理途径，而且可能对需要迅速干预和量身定制的患者管理的危及生命的疾病具有临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Immunology & Cell Biology 医学-免疫学

CiteScore

7.50

自引率

2.50%

发文量

审稿时长

4-8 weeks

期刊介绍： The Australasian Society for Immunology Incorporated (ASI) was created by the amalgamation in 1991 of the Australian Society for Immunology, formed in 1970, and the New Zealand Society for Immunology, formed in 1975. The aim of the Society is to encourage and support the discipline of immunology in the Australasian region. It is a broadly based Society, embracing clinical and experimental, cellular and molecular immunology in humans and animals. The Society provides a network for the exchange of information and for collaboration within Australia, New Zealand and overseas. ASI members have been prominent in advancing biological and medical research worldwide. We seek to encourage the study of immunology in Australia and New Zealand and are active in introducing young scientists to the discipline.